Results 101 to 110 of about 530,601 (300)
Molecular Oncology, EarlyView.Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen +9 more
wiley +1 more source
Sigma Receptors Modulation of Voltage-gated Ion Channels in Rat Autonomic Neurons [PDF]
, 2005 Sigma receptors have been implicated in the regulation of the cardiovascular system. Some of the cardiovascular effects of sigma receptors may be through the modulation of autonomic neurons.
Zhang, Hongling
core +1 more source
Sigma-1 Receptors and Neurodegenerative Diseases: Towards a Hypothesis of Sigma-1 Receptors as Amplifiers of Neurodegeneration and Neuroprotection [PDF]
, 1905 Sigma-1 receptors are molecular chaperones that may act as pathological mediators and targets for novel therapeutic applications in neurodegenerative diseases.
Lucke-Wold, B P +3 more
core +1 more source
Molecular Oncology, EarlyView.Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata +10 more
wiley +1 more source
Molecular Oncology, EarlyView.This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska +13 more
wiley +1 more source
Molecular Oncology, EarlyView.Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source
Expression of sigma receptors in human cancer cell lines and effects of novel sigma-2 ligands on their proliferation [PDF]
, 2018 A thesis submitted for the degree of Doctor of Philosophy University of Wolverhampton.Sigma receptors originally thought to be an opioid receptor is now categorized as a distinct class of receptor. There are two main subtypes, the sigma-1 receptor and an
Abbas, Haider
core
Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining
Molecular Oncology, EarlyView.IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis +3 more
wiley +1 more source
The controversial identity of the sigma-2 receptor with PGRMC1: is the PGRMC1/sigma-2 protein, that binds Abeta oligomer, made of two independent molecular entities? [PDF]
, 2015 Sigma-2 receptors are intriguing targets under study for their involvement in tumors and neurodegenerative diseases. However, the ‘sigma enigma’ is not over yet, with controversies about sigma-2 receptor identity.
ABATE, CARMEN rosa +4 more
core
Simple ammonium salts acting on sigma-1 receptors yield potential treatments for cancer and depression. [PDF]
, 2021 Sigma-1 and sigma-2 receptors are emerging therapeutic targets. We have identified that simple ammonium salts bind to these receptors and are effective in vivo.
David R. Ferry (8567838) +8 more
core